Selected research
Industry Growth & Trends
Global Large Molecule Drugs CDMO Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global Large Molecule Drugs CDMO market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Large Molecule Drugs CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Large Molecule Drugs CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Large Molecule Drugs CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the Large Molecule Drugs CDMO market include Patheon, Eurofins Scientific, Samsung Biologics, Catalent, Inc., Rentschler Biopharma SE, AGC Biologics, Recipharm AB, Siegfried Holding AG and FUJIFILM Diosynth Biotechnologies, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Large Molecule Drugs CDMO market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Large Molecule Drugs CDMO market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Large Molecule Drugs CDMO market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Large Molecule Drugs CDMO.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Large Molecule Drugs CDMO market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Large Molecule Drugs CDMO Market by Company
Patheon
Eurofins Scientific
Samsung Biologics
Catalent, Inc.
Rentschler Biopharma SE
AGC Biologics
Recipharm AB
Siegfried Holding AG
FUJIFILM Diosynth Biotechnologies
Scorpius
Ardena
Alcami
Cytiva
Thermo Fisher Scientific
Large Molecule Drugs CDMO Segment by Type
Cell Line Development
Large Molecule Drug Substance Development
Large Molecule Drugs CDMO Segment by Application
Biological Technology
Clinical
Pharmaceutical
Others
Large Molecule Drugs CDMO Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Large Molecule Drugs CDMO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Large Molecule Drugs CDMO and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Large Molecule Drugs CDMO.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Large Molecule Drugs CDMO companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Cell Line Development
- Large Molecule Drug Substance Development
Applications
- Biological Technology
- Clinical
- Pharmaceutical
- Others
Companies covered
- Patheon
- Eurofins Scientific
- Samsung Biologics
- Catalent, Inc.
- Rentschler Biopharma SE
- AGC Biologics
- Recipharm AB
- Siegfried Holding AG
- FUJIFILM Diosynth Biotechnologies
- Scorpius
- Ardena
- Alcami
- Cytiva
- Thermo Fisher Scientific
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Large Molecule Drugs CDMO Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Large Molecule Drugs CDMO Market Size by Region (2021-2032)
- 1.4.1 Global Large Molecule Drugs CDMO Market Size by Region (2021-2026)
- 1.4.2 Global Large Molecule Drugs CDMO Market Size by Region (2027-2032)
- 1.5 Key Regions Large Molecule Drugs CDMO Market Size (2021-2032)
- 1.5.1 North America Large Molecule Drugs CDMO Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Large Molecule Drugs CDMO Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Large Molecule Drugs CDMO Market Size Growth Rate (2021-2032)
- 1.5.4 South America Large Molecule Drugs CDMO Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Large Molecule Drugs CDMO Market Size Growth Rate (2021-2032)
2 Large Molecule Drugs CDMO Market by Type
- 2.1 Type Introduction
- 2.1.1 Cell Line Development
- 2.1.2 Large Molecule Drug Substance Development
- 2.2 Global Large Molecule Drugs CDMO Market Size by Type
- 2.2.1 Global Large Molecule Drugs CDMO Market Size Overview by Type (2021-2032)
- 2.2.2 Global Large Molecule Drugs CDMO Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Large Molecule Drugs CDMO Market Size Forecasted by Type (2027-2032)
- 2.3 Global Large Molecule Drugs CDMO Market Size by Regions
- 2.3.1 North America Large Molecule Drugs CDMO Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Large Molecule Drugs CDMO Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Large Molecule Drugs CDMO Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Large Molecule Drugs CDMO Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Large Molecule Drugs CDMO Market Size Breakdown by Type (2021-2026)
3 Large Molecule Drugs CDMO Market by Application
- 3.1 Type Introduction
- 3.1.1 Biological Technology
- 3.1.2 Clinical
- 3.1.3 Pharmaceutical
- 3.1.4 Others
- 3.2 Global Large Molecule Drugs CDMO Market Size by Application
- 3.2.1 Global Large Molecule Drugs CDMO Market Size Overview by Application (2021-2032)
- 3.2.2 Global Large Molecule Drugs CDMO Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Large Molecule Drugs CDMO Market Size Forecasted by Application (2027-2032)
- 3.3 Global Large Molecule Drugs CDMO Market Size by Regions
- 3.3.1 North America Large Molecule Drugs CDMO Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Large Molecule Drugs CDMO Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Large Molecule Drugs CDMO Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Large Molecule Drugs CDMO Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Large Molecule Drugs CDMO Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Large Molecule Drugs CDMO Industry Trends
- 4.2 Large Molecule Drugs CDMO Industry Drivers
- 4.3 Large Molecule Drugs CDMO Industry Opportunities and Challenges
- 4.4 Large Molecule Drugs CDMO Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Large Molecule Drugs CDMO Revenue (2021-2026)
- 5.2 Global Large Molecule Drugs CDMO Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Large Molecule Drugs CDMO Key Company Headquarters & Area Served
- 5.4 Global Large Molecule Drugs CDMO Company, Product Type & Application
- 5.5 Global Large Molecule Drugs CDMO Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Large Molecule Drugs CDMO Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Large Molecule Drugs CDMO Players Market Share by Revenue in 2025
- 5.6.3 2025 Large Molecule Drugs CDMO Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Patheon
- 6.1.1 Patheon Company Information
- 6.1.2 Patheon Business Overview
- 6.1.3 Patheon Large Molecule Drugs CDMO Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Patheon Large Molecule Drugs CDMO Product Portfolio
- 6.1.5 Patheon Recent Developments
- 6.2 Eurofins Scientific
- 6.2.1 Eurofins Scientific Company Information
- 6.2.2 Eurofins Scientific Business Overview
- 6.2.3 Eurofins Scientific Large Molecule Drugs CDMO Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Eurofins Scientific Large Molecule Drugs CDMO Product Portfolio
- 6.2.5 Eurofins Scientific Recent Developments
- 6.3 Samsung Biologics
- 6.3.1 Samsung Biologics Company Information
- 6.3.2 Samsung Biologics Business Overview
- 6.3.3 Samsung Biologics Large Molecule Drugs CDMO Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Samsung Biologics Large Molecule Drugs CDMO Product Portfolio
- 6.3.5 Samsung Biologics Recent Developments
- 6.4 Catalent, Inc.
- 6.4.1 Catalent, Inc. Company Information
- 6.4.2 Catalent, Inc. Business Overview
- 6.4.3 Catalent, Inc. Large Molecule Drugs CDMO Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Catalent, Inc. Large Molecule Drugs CDMO Product Portfolio
- 6.4.5 Catalent, Inc. Recent Developments
- 6.5 Rentschler Biopharma SE
- 6.5.1 Rentschler Biopharma SE Company Information
- 6.5.2 Rentschler Biopharma SE Business Overview
- 6.5.3 Rentschler Biopharma SE Large Molecule Drugs CDMO Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 Rentschler Biopharma SE Large Molecule Drugs CDMO Product Portfolio
- 6.5.5 Rentschler Biopharma SE Recent Developments
- 6.6 AGC Biologics
- 6.6.1 AGC Biologics Company Information
- 6.6.2 AGC Biologics Business Overview
- 6.6.3 AGC Biologics Large Molecule Drugs CDMO Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 AGC Biologics Large Molecule Drugs CDMO Product Portfolio
- 6.6.5 AGC Biologics Recent Developments
- 6.7 Recipharm AB
- 6.7.1 Recipharm AB Company Information
- 6.7.2 Recipharm AB Business Overview
- 6.7.3 Recipharm AB Large Molecule Drugs CDMO Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 Recipharm AB Large Molecule Drugs CDMO Product Portfolio
- 6.7.5 Recipharm AB Recent Developments
- 6.8 Siegfried Holding AG
- 6.8.1 Siegfried Holding AG Company Information
- 6.8.2 Siegfried Holding AG Business Overview
- 6.8.3 Siegfried Holding AG Large Molecule Drugs CDMO Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 Siegfried Holding AG Large Molecule Drugs CDMO Product Portfolio
- 6.8.5 Siegfried Holding AG Recent Developments
- 6.9 FUJIFILM Diosynth Biotechnologies
- 6.9.1 FUJIFILM Diosynth Biotechnologies Company Information
- 6.9.2 FUJIFILM Diosynth Biotechnologies Business Overview
- 6.9.3 FUJIFILM Diosynth Biotechnologies Large Molecule Drugs CDMO Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 FUJIFILM Diosynth Biotechnologies Large Molecule Drugs CDMO Product Portfolio
- 6.9.5 FUJIFILM Diosynth Biotechnologies Recent Developments
- 6.10 Scorpius
- 6.10.1 Scorpius Company Information
- 6.10.2 Scorpius Business Overview
- 6.10.3 Scorpius Large Molecule Drugs CDMO Revenue, Global Share and Gross Margin (2021-2026)
- 6.10.4 Scorpius Large Molecule Drugs CDMO Product Portfolio
- 6.10.5 Scorpius Recent Developments
- 6.11 Ardena
- 6.11.1 Ardena Company Information
- 6.11.2 Ardena Business Overview
- 6.11.3 Ardena Large Molecule Drugs CDMO Revenue, Global Share and Gross Margin (2021-2026)
- 6.11.4 Ardena Large Molecule Drugs CDMO Product Portfolio
- 6.11.5 Ardena Recent Developments
- 6.12 Alcami
- 6.12.1 Alcami Company Information
- 6.12.2 Alcami Business Overview
- 6.12.3 Alcami Large Molecule Drugs CDMO Revenue, Global Share and Gross Margin (2021-2026)
- 6.12.4 Alcami Large Molecule Drugs CDMO Product Portfolio
- 6.12.5 Alcami Recent Developments
- 6.13 Cytiva
- 6.13.1 Cytiva Company Information
- 6.13.2 Cytiva Business Overview
- 6.13.3 Cytiva Large Molecule Drugs CDMO Revenue, Global Share and Gross Margin (2021-2026)
- 6.13.4 Cytiva Large Molecule Drugs CDMO Product Portfolio
- 6.13.5 Cytiva Recent Developments
- 6.14 Thermo Fisher Scientific
- 6.14.1 Thermo Fisher Scientific Company Information
- 6.14.2 Thermo Fisher Scientific Business Overview
- 6.14.3 Thermo Fisher Scientific Large Molecule Drugs CDMO Revenue, Global Share and Gross Margin (2021-2026)
- 6.14.4 Thermo Fisher Scientific Large Molecule Drugs CDMO Product Portfolio
- 6.14.5 Thermo Fisher Scientific Recent Developments
7 North America
- 7.1 North America Large Molecule Drugs CDMO Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Large Molecule Drugs CDMO Market Size by Country (2021-2026)
- 7.3 North America Large Molecule Drugs CDMO Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Large Molecule Drugs CDMO Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Large Molecule Drugs CDMO Market Size by Country (2021-2026)
- 8.3 Europe Large Molecule Drugs CDMO Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Large Molecule Drugs CDMO Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Large Molecule Drugs CDMO Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Large Molecule Drugs CDMO Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Large Molecule Drugs CDMO Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Large Molecule Drugs CDMO Market Size by Country (2021-2026)
- 10.3 South America Large Molecule Drugs CDMO Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Large Molecule Drugs CDMO Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Large Molecule Drugs CDMO Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Large Molecule Drugs CDMO Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst